Quality and manufacturing

From the moment research and development begins to the time our medicines reach patients, Teva’s commitment to quality is uncompromising

Teva's extensive global operations network includes approximately 25,000 employees at more than 65 manufacturing sites in over 30 countries 01.

Here in Ireland, we have three main locations in the Republic of Ireland and one in Northern Ireland. 

teva-ireland-map-graphic_4.jpg

  • We have a large manufacturing site in Waterford which focuses on the manufacture and development of respiratory products for supply to the United States and around 30 other global markets. It includes an onsite research and development centre.
  • We have a manufacturing plant in Baldoyle in Dublin which makes the over-the-counter medication Sudocrem®, first developed in 1931 and now a multi-award winning, globally recognised product sold in over 50 countries.
  • We have a Commercial / Support office in Swords, near Dublin.
  • In Northern Ireland, we have manufacturing and research facilities in Larne, focussing on hormonal rings, implants and intrauterine devices.
Learn more about Teva in Ireland

 

We strive to deliver quality generic and specialty medicines to different markets - quickly and effectively. The team that makes this happen spans several areas of our business including Research & Development, Quality Assurance, Regulatory Affairs, scientific and logistical support, customer service, marketing and sales.

Quality Assurance

Teva’s commitment to quality is uncompromising and we manufacture according to the highest quality and compliance standards. This focus is evident at every stage of the development and production of our medicines.

All of our manufacturing processes are validated and products are tested and certified, using state-of-the-art testing equipment throughout the manufacturing process that ensures adherence to the highest quality and compliance standards.

Teva Global Operations is dedicated to optimising the performance of our global supply chain from the time we procure our first raw materials to the moment our medicines reach patients.

We know that a timely, reliable and cost-effective global distribution capability is critical to providing customers and patients with effective, high-quality products where and when they need them. Our high-volume, technologically-advanced distribution facilities allow us to deliver best-in-class products swiftly and reliably.

Teva has the benefit of being vertically integrated, which means that a major portion of our active pharmaceutical ingredients (APIs) are supplied by our own API manufacturing company, TAPI.

In fact, TAPI provides unique access to common and exclusive APIs right from the development stage, enabling the timely introduction of generic products to the market. 


References

  1. Back to contents.

    Based on 2019 Teva Global Operations internal data.

Share this article:

Date of preparation: December 2020
Reference: COB-IE-NP-00036